

Clinical Policy: Endometrial Ablation

Reference Number: PA.CP.MP.106

Effective Date: 05/18

Last Review Date: 8/31/2021

[Revision Log](#)
[Coding Implications](#)

Description

This policy describes the medical necessity guidelines for an endometrial ablation. Endometrial ablation is a minimally invasive surgical procedure used to treat premenopausal abnormal uterine bleeding. Although this procedure preserves the uterus, endometrial ablation is indicated for those who have no desire for future fertility. The two major classifications of endometrial ablation procedures are first generation resectoscopic techniques and second generation non-resectoscopic methods. Quality of life may improve following endometrial ablation procedures.

Policy/Criteria

- I. It is the policy of PA Health & Wellness that endometrial ablation using an FDA approved device is **medically necessary** when all the following criteria are met:
 - A. One of the following indications:
 1. Menorrhagia unresponsive to at least 3 months of hormonal or medical therapy (unless contraindicated to such therapy); or
 2. Abnormal uterine bleeding, including residual menstrual bleeding after at least 6 months of androgen therapy in a female to male transgender person;
 - B. Cervical cytology and gynecological exam excludes significant cervical disease;
 - C. Endometrial sampling prior to the procedure has excluded malignancy or hyperplasia;
 - D. No structural anomalies, such as fibroids or polyps that require surgery or represent a contraindication to an ablation procedure, or previous transmyometrial uterine surgery (including classical cesarean);
 - E. If anatomic or pathologic conditions exist that may result in a weakened myometrium, only a resectoscopic endometrial ablation is appropriate;
 - F. Does not have any of the following contraindications:
 1. Premenopausal with future desire for fertility;
 2. Untreated disorders of hemostasis;
 3. Pregnancy at time of procedure;
 4. Intrauterine device at time of procedure;
 5. Active pelvic infection.

- II. It is the policy of PA Health & Wellness that there is insufficient scientific evidence to support effectiveness for the following:
 - A. Photodynamic endometrial ablation procedures;
 - B. Endometrial ablation for the treatment of all other conditions than those specified above.

Background

Menstrual disorders are among the most prevalent gynecological health problems in the United States, and abnormal menstrual bleeding affects up to 30% of people at some time during their reproductive years.⁵ Endometrial ablation is a minimally invasive surgical procedure used to treat premenopausal, abnormal uterine bleeding.

CLINICAL POLICY

Endometrial Ablation

Endometrial ablation can also be used to treat residual menstrual bleeding in transgender men. Generally, masculinizing hormones cause cessation of menses within 2 – 6 months of initiation. Addition of a progestational agent or endometrial ablation may be considered for those wishing to completely cease menses.

Endometrial ablation encompasses several techniques of targeted destruction of the endothelial surface of the uterine cavity through a vast array of energy sources. While hysterectomies provide permanent relief from abnormal uterine bleeding, they are also associated with longer recovery times, higher rates of postoperative complications, substantial convalescent time and morbidity.^{9,10} Although endometrial ablation has a high success rate, there are specific cases of endometrial ablation failures in which the patient will return for repeat care, often for a hysterectomy.¹⁰ Among patients who return for hysterectomy after failure of endometrial ablation, endometriosis is the most common contributing diagnosis.²¹

Pregnancy following endometrial ablation can occur, and premenopausal patients should be counseled that an appropriate contraception method should be used.¹ However endometrial ablation is predominately indicated for patients who have no desire for future fertility.¹ Post-operative complications from endometrial ablation include: (1) pregnancy after endometrial ablation; (2) pain-related to obstructed menses (hematomata, post ablation tubal sterilization syndrome); (3) failure to control menses; (4) risk from preexisting conditions (endometrial neoplasia, cesarean section; and (5) infection.¹⁴ Uterine perforation has been reported in 0.3 percent of non-resectoscopic endometrial ablation procedures and 1.3 percent of resectoscopic ablations or resections.²²

Table 1: FDA-Approved Techniques Approved For Endometrial Ablation

Procedure ^{1,2,3}	System ^{1,2,13}	Device Size ¹ (mm)	Treatment Time ^{1,13} (min)	Amenorrhea Rate ²
Resectoscopic Ablation				
Laser Vaporization				37%
Electrosurgical Rollerball				25-60%
Transcervical resection of endometrium				26-40%
Radiofrequency Vaporization				N/A
Non-Resectoscopic Ablation				
Cryotherapy	Her Option	4.5	10–18	53%
Heated Free Fluid	Hydro ThermAblator	7.8	~ 14 *	71%
Microwave (no longer available in U.S.)		8.5	2.5–4.5	61%
Vapor ablation	Mara		2.0	
Radiofrequency Electricity	NovaSure	7.2	1.5	41%
Thermal Balloon	ThermaChoice	5.5	8.0	
Combined thermal and bipolar radiofrequency ablation device	Minerva		2.0	

* 3 minutes to heat the fluid to 90°C, 10 minutes to maintain that temperature to ablate the endometrium, and approximately 1 minute for the fluid to cool down allowing the device to be removed.

CLINICAL POLICY

Endometrial Ablation

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020 American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
58353	Endometrial ablation, thermal, without hysteroscopic guidance
58356	Endometrial cryoablation with ultrasonic guidance, including endometrial curettage, when performed
58563	Hysteroscopy, surgical; with endometrial ablation (eg, endometrial resection, electrosurgical ablation, thermoablation)

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
N92.0	Excessive and frequent menstruation with regular cycle
N92.1	Excessive and frequent menstruation with irregular cycle
N92.4	Excessive bleeding in the premenopausal period
N92.5	Other specified irregular menstruation
N92.6	Irregular menstruation, unspecified
N93.8	Other specified abnormal uterine and vaginal bleeding
N93.9	Abnormal uterine and vaginal bleeding, unspecified

Reviews, Revisions, and Approvals	Date	Approval Date
Policy developed	04/18	06/18
Added “previous transmyometrial uterine surgery” in I.D. References reviewed and updated.	09/18	02/19
Added additional FDA approved devices (i.e., Mara, Minerva) to table 1. References reviewed and updated. Specialist review.		
Added “abnormal uterine bleeding” as an indication and combined this with the residual menstrual bleeding after androgen therapy in a female to male transgender person indication. Removed reference to criteria in CP.MP.95 Gender Affirming Procedures. Added the following codes as medically necessary: N92.5, N92.6, N93.8, N93.9.		
Annual review completed. References reviewed and updated and reformatted for AMA style. Changed “members” to “members/enrollees.” Removed “experimental and investigation” from	8/31/2021	

CLINICAL POLICY

Endometrial Ablation

Reviews, Revisions, and Approvals	Date	Approval Date
II, changing to “insufficient evidence.” Specialty review completed. Added ThermaChoice to Table 1 per UpToDate reference “3”.		

References

1. Munro, MG. American College of Obstetricians and Gynecologists. "ACOG Practice Bulletin: Endometrial Ablation Number 81." Available at: <https://www.acog.org> Accessed June 15, 2021.
2. Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. *Am Fam Physician*. 2007 Jun 15;75(12):1813-9. PMID: 17619523.
3. Sharp HT. Endometrial ablation or resection: Resectoscopic techniques. Available at: <https://www.uptodate.com> Accessed June 15, 2021.
4. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 557: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. Available at: <https://www.acog.org> Accessed June 16, 2021.
5. Matteson KA, Boardman LA, Munro MG, Clark MA. Abnormal uterine bleeding: a review of patient-based outcome measures. *Fertil Steril*. 2009 Jul;92(1):205-16. doi: 10.1016/j.fertnstert.2008.04.023. Epub 2008 Jul 16. PMID: 18635169; PMCID: PMC2746391.
6. Frick KD, Clark MA, Steinwachs DM, Langenberg P, Stovall D, Munro MG, Dickersin K; STOP-DUB Research Group. Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. *Womens Health Issues*. 2009 Jan-Feb;19(1):70-8. doi: 10.1016/j.whi.2008.07.002. PMID: 19111789.
7. American College of Obstetricians and Gynecologists. Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 128. Diagnosis of Abnormal Uterine Bleeding: in Reproductive-Aged Women. Available at: <https://www.acog.org> Accessed June 16, 2021.
8. Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in non-gravid women of reproductive age. *Int J Gynaecol Obstet*. 2011 Apr;113(1):3-13.
9. Sowter MC. New surgical treatments for menorrhagia. *Lancet*. 2003 Apr 26;361(9367):1456-8. doi: 10.1016/S0140-6736(03)13140-6. PMID: 12727413.
10. Fergusson RJ, Lethaby A, Shepperd S, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. *Cochrane Database Syst Rev*. 2013 Nov 29;(11):CD000329. doi: 10.1002/14651858.CD000329.pub2. Update in: *Cochrane Database Syst Rev*. 2019 Aug 29;8:CD000329. PMID: 24288154.
11. Laberge P, Leyland N, Murji A, Fortin C, Martyn P, Vilos G; Clinical Practice-Gynaecology Committee, Leyland N, Wolfman W, Allaire C, Awadalla A, Dunn S, Heywood M, Lemyre M, Marcoux V, Potestio F, Rittenberg D, Singh S, Yeung G; Society of Obstetricians and Gynaecologists of Canada. Endometrial ablation in the management of abnormal uterine bleeding. *J Obstet Gynaecol Can*. 2015 Apr;37(4):362-79. doi: 10.1016/s1701-2163(15)30288-7. PMID: 26001691.
12. Lethaby A, Penninx J, Hickey M, Garry R, Marjoribanks J. Endometrial resection and ablation techniques for heavy menstrual bleeding. *Cochrane Database Syst Rev*. 2013 Aug

CLINICAL POLICY

Endometrial Ablation

- 30;(8):CD001501. doi: 10.1002/14651858.CD001501.pub4. Update in: Cochrane Database Syst Rev. 2019 Jan 22;1:CD001501. PMID: 23990373.
13. Sharp, H.T. Endometrial ablation: Non-resectoscopic techniques. Available at: <https://www.uptodate.com> Accessed June 15, 2021.
 14. Sharp HT. Endometrial ablation: postoperative complications. *Am J Obstet Gynecol*. 2012 Oct;207(4):242-7. doi: 10.1016/j.ajog.2012.04.011. Epub 2012 Apr 6. PMID: 22541856.
 15. El-Nashar SA, Hopkins MR, Creedon DJ, St Sauver JL, Weaver AL, McGree ME, Cliby WA, Famuyide AO. Prediction of treatment outcomes after global endometrial ablation. *Obstet Gynecol*. 2009 Jan;113(1):97-106. doi: 10.1097/AOG.0b013e31818f5a8d. Erratum in: *Obstet Gynecol*. 2010 Mar;115(3):663. PMID: 19104365; PMCID: PMC2977517.
 16. Food and Drug Administration. Class 2 Device Recall Gynecare Thermachoice III. Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID=142341> Accessed June 16, 2021.
 17. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline [published correction appears in *J Clin Endocrinol Metab*. 2021 May 08;:]. *J Clin Endocrinol Metab*. 2009;94(9):3132-3154. doi:10.1210/jc.2009-0345.
 18. The World Professional Association for Transgender Health Inc. (WPATH). Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th version. <https://www.wpath.org/publications/soc>.
 19. Kalampokas E, McRobbie S, Payne F, Parkin DE. Long-term incidence of hysterectomy following endometrial resection or endometrial ablation for heavy menstrual bleeding. *Int J Gynaecol Obstet*. 2017;139(1):61-64. doi:10.1002/ijgo.12259.
 20. Al-Shaikh G, Almalki G, Bukhari M, Fayed A, Al-Mandeel H. Effectiveness and outcomes of thermablate endometrial ablation system in women with heavy menstrual bleeding. *J Obstet Gynaecol*. 2017;37(6):770-774. doi:10.1080/01443615.2017.1292228.
 21. Riley KA, Davies MF, Harkins GJ. Characteristics of patients undergoing hysterectomy for failed endometrial ablation. *JSLs*. 2013;17(4):503-507. doi:10.4293/108680813X13693422520602.
 22. Sharp HT. An overview of Endometrial Ablation. Available at: <https://www.uptodate.com> Accessed June 15, 2021.
 23. Bofill Rodriguez M, Lethaby A, Grigore M, Brown J, Hickey M, Farquhar C. Endometrial resection and ablation techniques for heavy menstrual bleeding. *Cochrane Database Syst Rev*. 2019;1(1):CD001501. Published 2019 Jan 22. doi:10.1002/14651858.CD001501.pub5.
 24. National Institute for Clinical Excellence (NICE). Photodynamic endometrial ablation. *Interventional Procedure Guidance 47*. London, UK: NICE; 2004.